Anticipated $-0.16 EPS for VolitionRx Limited (VNRX) as of May, 10

April 17, 2018 - By Jenna Rose

VolitionRx Limited (NYSEAMERICAN:VNRX) Corporate Logo
Big Money Sentiment decreased to 1.2 in Q4 2017. It has change of 5.80, from 2017Q3’s 7. The ratio fall due to VolitionRx Limited positioning: 3 sold and 2 reduced. 2 funds took stakes and 4 increased stakes. Investors holded 9.30 million in 2017Q3 but now own 4.52 million shares or 51.36% less.
Royal Bank & Trust Of Canada holds 0% or 14,007 shs. Bridgeway Cap has invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Knoll Capital Lp owns 351,538 shs for 0.91% of their capital. Bessemer, a New Jersey-based fund reported 10,000 shs. Garrison Bradford And Associate invested in 15,500 shs. 10,335 are owned by Bancshares Of New York Mellon Corp. Northern Corporation invested in 22,714 shs or 0% of the stock. Geode Mgmt Ltd Com accumulated 100,890 shs or 0% of the stock. Creative Planning invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX). Brown Brothers Harriman accumulated 3,823 shs. Vanguard Gru Incorporated has 204,994 shs. Leisure Cap holds 74,863 shs. 11,219 are owned by Blackrock Inc. Lagoda Invest Lp accumulated 3.94% or 3.52M shs. Morgan Stanley invested 0% in VolitionRx Limited (NYSEAMERICAN:VNRX).

On May, 10 VolitionRx Limited (NYSEAMERICAN:VNRX)’s earnings release is expected by WallStreet, Faxor reports. Analysts expect change of 23.08 % or $0.03 from previous year’s $-0.13 earnings per share compared to current’s $-0.16 earnings per share. 6.67 % negative EPS growth is what Wall Street’s sees after $-0.15 reported EPS last quarter. VNRX reached $2.21 on during the last trading session after $0.05 change.VolitionRx Limited has volume of 11,062 shares. Since April 17, 2017 VNRX has declined 42.82% and is downtrending. VNRX underperformed the S&P 500 by 54.37%.

VolitionRx Limited, a life sciences company, focuses on developing blood tests to diagnose a range of cancers.The firm is worth $66.34 million. The firm is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform.Last it reported negative earnings. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants.

VolitionRx Limited (NYSEAMERICAN:VNRX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: